Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
6.38
-0.37 (-5.48%)
Jun 25, 2025, 1:31 PM - Market open

Actuate Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-25.31-27.29-24.74-20.16
Stock-Based Compensation
2.9720.420.65
Other Operating Activities
1.812.350.12-0.02
Change in Accounts Payable
-1.36-1.51.290.59
Change in Other Net Operating Assets
0.672.61.281.15
Operating Cash Flow
-21.21-21.84-21.63-17.79
Short-Term Debt Issued
-5.7--
Total Debt Issued
1.25.7--
Short-Term Debt Repaid
--0.2--
Total Debt Repaid
-0.2-0.2--
Net Debt Issued (Repaid)
15.5--
Issuance of Common Stock
23.9623.96--
Other Financing Activities
-1.92-1.93--
Financing Cash Flow
23.0327.534.1319.26
Net Cash Flow
1.825.68-17.491.46
Levered Free Cash Flow
-12.7-12.39-12.64-
Unlevered Free Cash Flow
-12.69-12.38-12.61-
Change in Net Working Capital
0.82-1.35-2.57-
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q